Why Passage Bio, Inc.’s (PASG) Stock Is Down 5.03%
As of Tuesday, January 13, Passage Bio, Inc.’s PASG share price has dipped by 5.03%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington’s disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania’s Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
Commentary & Analysis
Why Passage Bio, Inc.’s (PASG) Stock Is Down 10.66%
As of Tuesday, January 13, Passage Bio, Inc.’s PASG share price has dipped by 10.66%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Passage Bio, Inc.’s (PASG) Stock Is Down 6.70%
As of Monday, January 12, Passage Bio, Inc.’s PASG share price has dipped by 6.70%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Passage Bio, Inc.’s (PASG) Stock Is Down 11.54%
As of Monday, January 12, Passage Bio, Inc.’s PASG share price has dipped by 11.54%, which has investors questioning if this is right time to buy.Tudor Pop
Why Passage Bio, Inc.’s (PASG) Stock Is Up 5.13%
As of Friday, January 09, Passage Bio, Inc.’s PASG share price has surged by 5.13%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | PASG | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $15.0 | $288.9 | 8% |
|
| Shares Out (Mil) | 3.2 | 54.0 | 11% |
|
| Institutional Ownership | 99.0% | 93.1% | 84% |
|
| Float (Mil) | 3.2 | 41.4 | 8% |
|
| Beta | 1.43 | 0.94 | 80% |
|
| Avg Daily Volume (000s) | 17 | 480 | 20% |
|
| Price Change (52-week) |
(34.6%) | 59.9% | 22% |
|
| Growth | PASG | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | 16.5% | (10.1%) | 66% |
|
| EPS (5yr) | 24.4% | 15.9% | 74 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 17.3% | (15.6%) | 77% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($2.820) | ($11.340) | ($10.390) | |
| Month Ago EPS | ($2.820) | ($11.340) | ($10.390) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 1 | 2 | |
| Three Months Ago EPS | ($2.528) | ($9.358) | ($7.680) | |
| Year/Year Chg | 15.7% | (21.0%) | (36.4%) | |
| Financials | PASG | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($36) | ($43) | 19% |
|
| EPS (TTM) | ($11.309) | ($1.500) | 4% |
|
| Operating Cash Flow (TTM) (Mil) | ($34) | ($31) | 12% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($10) | $190 | 2% |
|
| Valuation | PASG | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.37 | 2.84 | 68% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | PASG | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (69.2%) | (47.7%) | 9% |
|
| ROE | (169.1%) | (55.0%) | 5% |
|
| Liabilities to Assets | 82.3% | 29.6% | 76% |
|
| F-Score | 2 | 3 | 7% |
|
Passage Bio, Inc. did not pass any screens on 9/2/2026.
